Twist Bioscience (TWST) Projected to Post Earnings on Monday

Twist Bioscience (NASDAQ:TWST) is expected to announce its Q2 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $92.00 million for the quarter. Twist Bioscience has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.75) EPS. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $39.24 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $39.24 and its 200 day moving average price is $44.07. Twist Bioscience has a 52 week low of $33.16 and a 52 week high of $60.90. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -11.61 and a beta of 2.34.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the transaction, the chief executive officer now owns 667,318 shares in the company, valued at approximately $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the sale, the director now directly owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,432 shares of company stock valued at $1,038,170. Company insiders own 3.01% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Guggenheim set a $50.00 price objective on Twist Bioscience in a research note on Friday, March 28th. Finally, Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.